Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
about
sameAs
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentNext-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic LeukemiaALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitorsStructural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Current developments in molecular monitoring in chronic myeloid leukemiaInterferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML PatientsIntegrative network modeling approaches to personalized cancer medicineA phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasClinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluidPractical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.Best Practices in Chronic Myeloid Leukemia Monitoring and ManagementQuantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.A review of the European LeukemiaNet recommendations for the management of CML.Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.New Methodologies in the Molecular Monitoring of CML.Present and future of molecular monitoring in chronic myeloid leukaemia.Current trends in molecular diagnostics of chronic myeloid leukemia.Monitoring disease burden in chronic myeloid leukemia: Past, present, and future.Molecular monitoring of chronic myeloid leukemia: present and future.
P2860
Q26766299-1EBF8624-967D-4139-885C-E68E6DB144E5Q26781271-C56777C5-6B85-4C83-8EB1-AB981BE2448EQ26799954-DD8A612F-181E-4B21-9899-EBB3A20DBE19Q27310990-C46A0B5C-31D5-4322-8C44-E1D8FCC15BD7Q27853214-7875C194-3533-4639-86CC-B1FAC2105212Q28066148-F33260FC-C8A2-4FA1-8728-6ADF420FD50BQ28552307-AF1E24A3-C427-46FF-A0E2-9F239756D767Q28602016-55555241-2417-4607-85E7-C5BD43FF649EQ33411250-9D037560-158F-4208-BBBA-FCBD626165F6Q33595764-A679CE20-01FB-4240-B0CE-55546270A260Q33841347-4230FCE7-1BDC-44EE-8049-7570902E4573Q34417824-114644E4-012B-4C34-93EC-7B5BBBDEDF04Q35104426-668F17FB-8276-47BC-ABFB-34E090D349D5Q35126258-8CDF7108-38DC-4598-B555-E820A6A6A096Q35596310-DBEDFDF5-F9F6-4B1A-9F78-AFBF8B71A26AQ35602127-FF6FD732-F046-46CD-A96F-0818094642EBQ35610140-21E86D6E-D164-4473-9458-B2DF931DD081Q35731623-E58658F8-EA8B-405E-8A91-05BEA29751F0Q36093137-BDC29DFF-9E88-40FF-AD10-C6E61CA74ED6Q36544560-1A525B25-B181-40A2-9ACB-5B74A6EF6854Q36884361-7151EFF4-DF55-4309-8C74-A9775A32D518Q36939131-3860CFD9-0795-4F57-BEDF-8573E067CED5Q37026032-222E5EE6-947D-494A-A427-8C5FDD964661Q37306997-D3FC8882-C1F6-435E-A227-21D807559852Q37627944-5AB599BC-C964-4616-9BC0-6FEBE578FD58Q37696776-F1160BAB-C35A-4555-8EDC-4C09D851E197Q38199143-0E56C00E-2C90-4225-9788-206F8CEA1D1FQ38216677-2FCD086F-983D-4AC0-94F1-158190BFD1EFQ38260343-A9C32C10-09D4-4962-8580-C5A4187404FDQ38363058-D3E3820F-D6AF-4321-9847-7167C66EB35BQ38392676-F8337782-8036-4973-BFCC-5927CCEFF217Q38478174-86D0174F-8CB5-4CCF-99FF-43EABC744547Q38562354-17E8CEB4-5B2B-4C8B-B7B5-523F734EE228Q38672646-13E741A2-2EC9-4736-A514-5FA5AC148B30Q38698520-01B72587-7A0E-42BA-9A9A-CEA969991C90Q38762203-F57DAEE8-024F-462A-B659-807E38219970Q38762631-819CA38B-FAD3-498C-813F-CA09489D9DFCQ38787015-1CC6521B-2FFC-41F5-9EAF-1D5BF23469BDQ38802249-2087268C-2BBE-4073-841D-8551264FD974Q38828713-942BAF1B-19BA-46FE-9448-85D2AC2CA1E2
P2860
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Unraveling the complexity of t ...... g of the BCR-ABL kinase domain
@en
Unraveling the complexity of t ...... g of the BCR-ABL kinase domain
@nl
type
label
Unraveling the complexity of t ...... g of the BCR-ABL kinase domain
@en
Unraveling the complexity of t ...... g of the BCR-ABL kinase domain
@nl
prefLabel
Unraveling the complexity of t ...... g of the BCR-ABL kinase domain
@en
Unraveling the complexity of t ...... g of the BCR-ABL kinase domain
@nl
P2093
P50
P921
P1433
P1476
Unraveling the complexity of t ...... g of the BCR-ABL kinase domain
@en
P2093
Adela Brouckova
Alexander Kohlmann
Andreas Roller
Barbara Giannini
Caterina De Benedittis
Claudia Venturi
David Horner
Domenico Russo
Fausto Castagnetti
Federica Cattina
P304
P356
10.1182/BLOOD-2013-03-487728
P407
P50
P577
2013-06-21T00:00:00Z